全文获取类型
收费全文 | 38640篇 |
免费 | 4084篇 |
国内免费 | 2667篇 |
专业分类
耳鼻咽喉 | 277篇 |
儿科学 | 826篇 |
妇产科学 | 498篇 |
基础医学 | 3572篇 |
口腔科学 | 573篇 |
临床医学 | 5693篇 |
内科学 | 5002篇 |
皮肤病学 | 477篇 |
神经病学 | 1785篇 |
特种医学 | 1194篇 |
外国民族医学 | 7篇 |
外科学 | 2666篇 |
综合类 | 7957篇 |
现状与发展 | 7篇 |
一般理论 | 5篇 |
预防医学 | 3796篇 |
眼科学 | 943篇 |
药学 | 4533篇 |
52篇 | |
中国医学 | 2700篇 |
肿瘤学 | 2828篇 |
出版年
2024年 | 128篇 |
2023年 | 579篇 |
2022年 | 1356篇 |
2021年 | 1733篇 |
2020年 | 1489篇 |
2019年 | 1194篇 |
2018年 | 1250篇 |
2017年 | 1262篇 |
2016年 | 1110篇 |
2015年 | 1782篇 |
2014年 | 2303篇 |
2013年 | 2195篇 |
2012年 | 3198篇 |
2011年 | 3420篇 |
2010年 | 2543篇 |
2009年 | 2106篇 |
2008年 | 2388篇 |
2007年 | 2426篇 |
2006年 | 2312篇 |
2005年 | 1923篇 |
2004年 | 1466篇 |
2003年 | 1464篇 |
2002年 | 1132篇 |
2001年 | 999篇 |
2000年 | 812篇 |
1999年 | 626篇 |
1998年 | 398篇 |
1997年 | 363篇 |
1996年 | 252篇 |
1995年 | 205篇 |
1994年 | 195篇 |
1993年 | 102篇 |
1992年 | 127篇 |
1991年 | 92篇 |
1990年 | 89篇 |
1989年 | 79篇 |
1988年 | 58篇 |
1987年 | 53篇 |
1986年 | 36篇 |
1985年 | 32篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 15篇 |
1980年 | 9篇 |
1979年 | 9篇 |
1975年 | 8篇 |
1974年 | 5篇 |
1973年 | 8篇 |
1970年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Kuo-yi Jade Chang MHealthEc MHM BSc Lisa Lorraine Dillon MSpecEd BPsych Lil Deverell COMS PhD MEd GradDipO&M BEd Mei Ying Boon PhD BOptom FAAO Lisa Keay PhD MPH BOptom 《Clinical & experimental optometry》2020,103(4):434-448
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual. 相似文献
3.
4.
5.
Haochu Li Xiaoming Li Lai Sze Tso Shan Qiao Eleanor Holroyd Yuejiao Zhou 《Vulnerable children and youth studies》2016,11(2):173-179
In HIV/AIDS research, few studies to date have evaluated ways to improve parental HIV disclosure practices using feedback from HIV-negative children who have recently experienced this event. We conducted semi-structured in-depth interviews with 20 children (aged 6–15) who were partially to fully aware of their parents’ HIV status in rural Guangxi, China. Of the 20 children, eight children who were of older age (11.38 years in average) endorsed parental HIV disclosure, five discouraged it and seven expressed uncertainty. Children’s different experiences and attitudes towards disclosure were seen to be associated with their family dynamics (especially the parent–child relationship), social support and care, experiences of stigma and discrimination, psychosocial suffering, comprehension of the disease and the children’s age. Our study contributes to building a child-centered comprehensive understanding for Chinese parental HIV disclosure. It is imperative that counselors and community advocates assess and help parents achieve optimal readiness preceding disclosure of their illness to their HIV-negative children. 相似文献
6.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
8.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献9.
目的:分析鼻塞式同步间歇正压通气(NIPPV)联合布地奈德雾化治疗ARDS(新生儿急性呼吸窘迫综合征)疾病的临床应用效果。方法:纳入病例是2017年5月—2019年11月收治的104例ARDS新生儿,随机平均分为两组。参照组52例采纳CPAP(持续气道正压通气通气)治疗,实验组52例采纳NIPPV+布地奈德雾化治疗,对比两组呼吸机通气时间、用氧时间、住院时间、血气指标以及并发症发生情况。结果:实验组呼吸机通气时间、用氧时间、住院时间均明显短于参照组,差异有统计学意义P<0.05;实验组治疗3 d后PaCO2明显低于参照组,实验组治疗3 d后PH以及PaO2明显高于参照组,差异有统计学意义P<0.05;实验组并发症发生率(3.85%,2/52)明显低于参照组(21.15%,11/52),差异有统计学意义P<0.05。结论:NIPPV+布地奈德雾化可有效缩短ARDS患者机械通气时间,改善血气指标,降低并发症发生率,值得借鉴。 相似文献
10.